Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBP-EC01 in Patients with E. Coli Urinary Tract Colonization
NCT04191148Phase 1Completed
- Sponsor
- Locus Biosciences
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- CRISPR-Cas9, Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asymptomatic bacteriuria (ASB) comparing LBP-EC01 Arm with Placebo Arm (2 arms). Primary endpoints: Number of Participants With Treatment-related Adverse Events as Assessed by DAIDS v2.1 at 35 days, Pharmacokinetics of LBP-EC01: Cmax at 28 days and 2 more. Started Dec 2019; status: completed.
02
Drugs
LBP-EC01
03
Conditions
asymptomatic bacteriuria (ASB)
Beyond the preview
Go deeper on NCT04191148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191148.